Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab-IRDye 800CW for Malignant Glioma Imaging
NCT02855086Phase 2Terminated
- Sponsor
- Eben Rosenthal
- Start
- Oct 2016
- Primary completion
- Nov 2016
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab-IRDye 800CW in malignant glioma, sponsored by Eben Rosenthal. Started Oct 2016; status: terminated.
02
Drugs
cetuximab-IRDye 800CW
03
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT02855086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02855086.